Nivolumab and anti-HCV activity, a case report

References

• Kähler KC, Hassel JC, Heinzerling L, et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges. 2016;14(7):662–681.
   Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase ½ dose escalation and expansion trial. Lancet Oncol. 2017;389(10088):2492–2502.
   Google Scholar
• Moreno-Cubero E, Larrubia R. Specific CD8+ T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol. 2016;22(28):6469–6483.
   Google Scholar
• Sangro B, El-Khoueiry AB, Crocenzi TS, et al. P1318: phase 1 dose escalation study of the safety, immunoregulatory activity, pharmacokinetics, and preliminary antitumor activity of nivolumab in advanced hepatocellular carcinoma in patients with or without chronic viral hepatitis B. J Hepatol. 2015;62:849.
   Google Scholar
• FDA grants priority review to nivolumab for advanced liver cancer. HemOnc Today. 2017;18(15):46.
   Google Scholar
• Cheng H, Sun G, Chen H, et al. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. Am J Cancer Res. 2019;9(8):1536–1545.
   Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III trial. J Clin Oncol. 2019; 38(3): 193–202.
   Google Scholar
• De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68(6):1181–1190.
   Google Scholar
• Lake AC. Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy. AIDS. 2017;31(15):2115–2118.
   Google Scholar
• Koksal AS, Toka B, Eminler AT, et al. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma. Ann Oncol. 2017;28(12):3103–3104.
   Google Scholar
• Pandey A, Ezemenari S, Liaukovich M, et al. A rare case of pembrolizumab-induced reactivation of hepatitis B. Case Rep Oncol Med. 2018: 5985131.
   Google Scholar
• Cho H, Kang H, Lee HH, et al. Programmed cell Death 1 (PD-1) and Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in viral hepatitis. Int J Mol Sci. 2017;18(7):1517.
   Google Scholar
• Gardiner D, Lalezari J, Lawitz E, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PloS ONE. 2013;8(5):e63818.
   Google Scholar
• Tio M, Rai R, Ezeoke OM, et al. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur J Cancer. 2018;104:137–144.
   Google Scholar
• Hosry J, Naing A, Torres H. 2226. Immune checkpoint inhibitors in solid tumor patients with chronic hepatitis c virus infection: a prospective case-series. Open Forum Infect Dis. 2018;5(1):658.
   Google Scholar
• Fuller MJ, Callendret B, Zhu B, et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci. 2013;110(37):15001.
   Google Scholar
• Salem ML, El-Badawy A. Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World J Hepatol. 2015;7(23):2449–2458.
   Google Scholar
• Wieland S, Makowska Z, Campana B, et al. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology. 2014;59(6):2121–2130. .
   Google Scholar
• Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med. 2000;191(8):1269–1280.
   Google Scholar